Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874596 | 0.98 | ACHE (0.59) | ACHECHRM5ADRA2CSMN1; SMN2CCR1 | |
| SCHEMBL25856576 | 0.90 | ACHE (0.51) | ACHECHRM5ADRA2CSMN1; SMN2CCR1 | |
| SCHEMBL2842528 | 0.90 | ACHE (0.47) | ACHECHRM5ADRA2CCCR1 | |
| SCHEMBL13874822 | 0.86 | ACHE (0.50) | ACHECHRM5ADRA2CSMN1; SMN2CCR1 | |
| SCHEMBL26706476 | 0.82 | ACHE (0.41) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 | |
| SCHEMBL22565125 | 0.82 | NCF1 (0.42) | ACHECHRM5ADRA2C | |
| SCHEMBL2848471 | 0.81 | CYP1A2 (0.42) | ACHECHRM5ADRA2CCHRM3 | |
| SCHEMBL25856481 | 0.78 | ACHE (0.60) | ACHECHRM5ADRA2C | |
| SCHEMBL11596303 | 0.78 | CHRM5 (0.84) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 | |
| SCHEMBL5376134 | 0.78 | CHRM5 (0.84) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669350-B1 | PIPERIDINE DERIVATIVES | MSD KK (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7834182-B2 | histamine H3 receptor antagonists; metabolic disorders, sleep disorders, cardiovascular disorders, alcoholism, drug addiction, memory disorders, Alzheimer's, Parkinson's disease; 2-(4-piperidinylpiperidinyl)pyrimidine compounds such as 2-[(4-piperidin-1-yl)piperidin-1-yl]-5-(3-pyridyl)pyrimidine | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090203710-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7547693-B2 | Such as N-methyl-N-(1-methylpiperidin-4-yl)-4-[4-(piperidin-1-yl)piperidin-1-yl]benzamide; histamine h3-antagonists | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1669350-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-4367232-A | ANOREXIGENIC AGENTS,ANESTHETICS | FORDONAL, S.A. (ES) | 1983-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | ACHE 2795/4885CHRM5 154/4885ADRA2C 109/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | ACHE 2562/4885CHRM5 160/4885ADRA2C 115/4885 |
| US-20070105901-A1 | Novel piperidine derivative | HRH3, OPRM1, OPRK1 | ACHE 518/4885CHRM5 40/4885ADRA2C 130/4885 |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | ACHE 2631/4885CHRM5 2233/4885ADRA2C 314/4885 |
| US-20090203710-A1 | Novel piperidine derivative | HRH3, OPRM1, HRH4 | ACHE 580/4885CHRM5 41/4885ADRA2C 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.